The Cancer Research Collaboration Partners with Diabetes Prevention Program Provider Blue Mesa Health with California Residen...
December 06 2018 - 2:32PM
The Cancer Research Collaboration (CRC), a non-profit organization
dedicated to expanding the availability of cutting-edge cancer
research, in partnership with RadNet, Inc. (Nasdaq:RDNT), a
national market leader providing high-quality, cost-effective
diagnostic imaging services through a network of fully-owned and
operated outpatient imaging centers, are, once again, proud to work
in conjunction with Blue Mesa Health’s (“Blue Mesa”) Transform
diabetes prevention program.
Since 2016, Blue Mesa’s CDC-recognized diabetes prevention
programs Transform and Transformemos have been helping stem the
tide of rising chronic disease-related health costs — a situation
where approximately one-third of Americans is prediabetic. The
programs are based on the Centers for Disease Control and
Prevention’s (CDC) landmark National Diabetes Prevention Program.
Transform and Transformemos combine software, home health
monitoring via wireless scales, activity trackers and remote health
coaching to guide participants through a twelve-month lifestyle
change program.
Since joining forces earlier this year to deliver the program to
patients in New York, CRC, RadNet and Blue Mesa have decided to
expand their collaboration to California patients. Similar to NY,
the Transform program will be provided to California CRC patients
who are at risk or are cancer survivors and meet the program
criteria. The goal is for participants to lose approximately 5-7%
of their body weight and add 150 minutes of moderate physical
activity over 52 weeks, which is correlated with a 58% reduction in
risk for type 2 diabetes. These are important goals for at-risk
patients and breast cancer survivors. Maintaining a healthy BMI can
reduce the risk of developing breast cancer and chronic conditions
such as type 2 diabetes.
For more information about the partnership or the program,
visit: www.cancerresearchcollaboration.org/blue-mesa.
About Blue Mesa Health
Blue Mesa is a digital therapeutics company with headquarters in
New York, NY and Vancouver, BC. Blue Mesa provides digital
therapeutics programs in over 5 countries and several languages,
with programs based on the CDC's National Diabetes Prevention
Program. In the United States, employers, health plans, accountable
care organizations, and hospital systems are recognizing the return
on investment provided by culturally tailored and digitally
delivered preventive health programs. Blue Mesa has raised funding
from Nimbus Synergies Inc., Pallasite Ventures, Stanley Park
Ventures Inc., and publicly traded technology firm Mobio
Technologies Inc. and other investors. For more information, visit
www.bluemesahealth.com.
About the Cancer Research Collaboration
The Cancer Research Collaboration (CRC) is a non-profit
organization dedicated to expanding the availability of
cutting-edge cancer research. CRC assists investigators,
pharmaceutical companies, and CROs in identifying new agents and
technologies for diagnosis and treatment of diseases. CRC builds
collaborations to foster innovation in research, education and
supportive programs aimed at benefiting patients living with cancer
or moving beyond it. For more information, visit
www.cancerresearchcollaboration.org.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding,
fixed-site diagnostic imaging services in the United States based
on the number of locations and annual imaging revenue. RadNet has a
network of 341 owned and/or operated outpatient imaging centers. In
addition, RadNet provides radiology information technology
solutions, teleradiology professional services and other related
products and services to customers in the diagnostic imaging
industry. For more information, visit www.radnet.com.
CONTACT:
Curtis Duggan, CEO and Co-Founder
press@bluemesahealth.com
1.347.468.3343
RadNet (NASDAQ:RDNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RadNet (NASDAQ:RDNT)
Historical Stock Chart
From Apr 2023 to Apr 2024